Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

European Commission approves Epidyolex for tuberous sclerosis complex

April 20, 2021

Brain injury modulates bone marrow cells to reduce neuroinflammation

April 19, 2021

Autotaxin inhibitor BIO-32546 for neuropathic pain

April 19, 2021

New PROTAC induces degradation of hematopoietic prostaglandin D synthase

April 19, 2021

Yale begins phase I study of BMS-984923 for Alzheimer's disease

April 16, 2021

Praxis initiates phase II/III trial of PRAX-114 for major depressive disorder

April 16, 2021

FDA approves IND for phase I study of MLC-1501 in post-TBI recovery

April 15, 2021

H1R deficiency in mouse cholinergic neurons involved in schizophrenia negative symptom pathogenesis

April 15, 2021

Longeveron reports final phase I data on Lomecel-B in Alzheimer's disease

April 14, 2021

Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor

April 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis
BioWorld
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...